Liq-NOL Efficacy in Pediatric Patients With Down Syndrome

Withdrawn before enrolling · Phase 2 · Has a placebo group

Conditions studied: Down Syndrome

In brief

The purpose of this study is to measure the effects of LiQ-NOL supplementation on language production using the Clinical Evaluation of Language Fundamentals test, language sampling using the mean length of utterance test, and speech articulation using the Goldman-Fristoe Test of Articulation.

Key facts

Study ID
NCT00891917
Run by
Children's Hospital Medical Center, Cincinnati
People needed
0
Starts
2005-01-01
Expected to finish
2012-12-01
Last updated by the study team
2020-09-09

Who can join

Age: 6 and older, up to 16. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.